Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Why Travere Therapeutics Stock Got Trounced on Tuesday A regulatory decision on a top investigational drug won't be coming as soon as hoped.
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS On January 13, 2026, Travere Therapeutics (
NASDAQ: TVTX ) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The news sent shockwaves through the biotech sector, causing
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved.
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors Travere Therapeutics (TVTX) shows strong earnings momentum, a bullish technical uptrend, and a current consolidation phase, presenting a potential breakout setup for growth investors.
Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup Travere Therapeutics (TVTX) shows strong high-growth momentum with surging sales and a positive technical setup, signaling a potential breakout.
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (
NASDAQ: LGND ) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,
Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat The stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug.
Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments Travere Therapeutics (TVTX) Q3 2025 earnings crush expectations, driven by strong FILSPARI sales. Revenue soared 160% year-over-year, sparking an 11.7% stock surge.
